FASTinov Showcases Latest Customer Evaluations Demonstrating Same-Shift Results at ECCMID 2024

FASTinov Showcases Latest Customer Evaluations Demonstrating Same-Shift Results at ECCMID 2024

April 30th 2024

(Barcelona, Spain) – FASTinov, the leading ultra-rapid Antimicrobial Susceptibility Test, proudly announces its successful participation at the 34th Edition of ECCMID, now called ESCMID Global, held from 27 to 30 of April in Barcelona, Spain.

The congress, renowned as a paramount gathering for clinicians, researchers, and industry leaders in the field of clinical microbiology and infectious diseases, provided an exceptional platform for FASTinov to showcase how its ultra-rapid AST is providing susceptibility reports in under 2 hours in several customer and demonstration sites.

Throughout the event, FASTinov engaged with customers, strategic partners, distributors, and industry peers, fostering meaningful discussions and collaborations. At booth D39, attendees had the opportunity to explore FASTinov’s ultra-rapid AST solutions, designed to facilitate the transition into targeted therapy within the same shift of diagnosis in cases of severe sepsis or bloodstream infections, improving clinical outcomes, reducing length of stay and hospital costs, and addressing the surge of antimicrobial resistance.

Additionally, FASTinov presented compelling scientific posters highlighting the usage of the technology in customer and demonstration sites. These posters underscored the real-world evidence of the impact of FASTinov’s solutions in clinical settings, further validating the ability of providing accurate AST results in the same shift the blood cultures flag positive.

“We are thrilled to once again be part of this prestigious congress, which serves as a cornerstone in our industry’s calendar,”
said Nuno Afonso, CEO of FASTinov.
“This event has enabled us to not only showcase our latest milestones but also to engage with key stakeholders, further reinforcing our commitment to advancing healthcare by making a stand against antimicrobial resistance.”

FASTinov extends its gratitude to the organizers, sponsors, partners, and attendees for contributing to the success of the event. As a company dedicated to driving innovation and making a positive impact in healthcare, FASTinov looks forward to continued collaboration and advancements in the field of clinical microbiology and infectious diseases.
For more information about FASTinov and the fastest AST in the world, please visit

About FASTinov

FASTinov is a leading innovator in rapid antimicrobial susceptibility testing, dedicated to revolutionizing patient care in sepsis contexts. With a mission to transform severe bacterial infection management in sepsis patient by providing actionable same-shift results, FASTinov’s cutting-edge technology offers healthcare professionals unprecedented timely insights for targeted treatment decisions.

Share with friends